GlassScriptPhysician profile
David A Taryle
NPI 1780688200
$1,056.22
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $188 · 2021: $94.52 · 2022: $292.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.08 | 2019-2022 | |
| Grifols USA, LLC | $176.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $106.44 | 2019-2022 | |
| Genentech USA, INC. | $90.77 | 2019 | |
| Mylan Specialty L.P. | $64.29 | 2019-2022 | |
| Insmed, INC. | $43.76 | 2020 | |
| Gilead Sciences, INC. | $38.23 | 2019-2022 | |
| Harmony Biosciences LLC | $33.78 | 2021 | |
| Merck Sharp & Dohme LLC | $33.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.10 | 2019 | |
| Resmed Corp | $21.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.06 | 2019 | |
| Shire North American Group INC | $17.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.43 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $15.54 | 2021 | |
| Genzyme Corporation | $15.09 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Taryle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.